HAI Holds Workshops on EU Medicines Policy & Access to Medicines in Eastern Europe

by BOBBI KLETTKE, Communications

Access to medicines is a key component of the human right to health. Although the European Union (EU) and its Member States are committed to universal and equitable access to healthcare, many patients across Europe still suffer inequalities in medicines availability and affordability. This is particularly the case in Eastern European countries.

Abysmal decisions: Why the EC’s medicinal units shouldn’t be moved to DG Industry

Last week, European Commission (EC) president-elect, Jean-Claude Juncker, announced his plan to move the units responsible for pharmaceutical policy from their rightful place at DG Health to the commercially-focused DG for Internal Market, Industry, Entrepreneurship and SMEs.
Health Action International (HAI) Europe and other civil society organisations working on medicines policy were shocked and outraged.

World Health Assembly: HAI and ARC intervention on antimicrobial resistance, including antibiotic resistance

by TIM REED and SHILA KAUR (on behalf of HAI and the Antibiotic Resistance Coalition)

In the face of what is undoubtedly a global health emergency, we welcome this resolution and commend Member States and the Secretariat for their action.

The antibiotic resistance crisis demands strong global leadership from both the Assembly and the Secretariat.

Enhancing accountability in the medicines market: The Medicines Transparency Alliance


Roberto Pagdanganan, MeTA Philippines Chair, Renee Vasbinder, HAI,
Cecile Sison, MeTA Philippines Country Coordinator, Tim Reed, HAI, and
Deirdre Dimancesco, WHO, at the 2014 MeTA Philippines Forum.
(Photo courtesy of MeTA Philippines.)

At least a third of the world’s population—over 2 billion men,

Statement on Medicines Patent Pool

HAI Global and HAI Europe congratulate the Medicines Patent Pool (MPP) on the licensing agreement with generic companies, most notably Aurobindo. The sublicenses are a major step forward in the development of an effective MPP and will have a tangible impact on the lives of many patients and promise the prospect of real improvements in global Access to Medicines.

DG Trade State of Play reveals EU's ambitions for IP protection in FTAs

The EU will not be changing its aggressive approach to IP protection in bilateral trade agreements, according to the updates that representatives from the European Commission gave at a State of Play meeting with civil society on June 27, 2011. Despite years of opposition and outrage by the global public health community, the EU continues to pursue high IP standards in trade deals with developing countries.

Conflicts of Interest and the Future of Financing for WHO.

Statement on WHO governance and the Management of Conflicts of Interest and the Future of Financing for WHO.

We write to express our concerns about governance of the World Health Organization (WHO) and other public health bodies, as regards the management of conflicts of interest.

WHO and other public health institutions have complex relations with commercial entities that supply health care products and services.